Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy

Abstract A major challenge in evaluating the success of HIV eradication approaches is the need for accurate measurement of persistent HIV during effective antiretroviral therapy (ART). Previous studies have reported that the anti-HIV antibody assay “luciferase immuno-precipitation systems (LIPS)” ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang Zhang, Mohammed M. Morshed, Kajsa Noyan, Aman Russom, Anders Sönnerborg, Ujjwal Neogi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/43034dd2fb8a41749587f2f644896a3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43034dd2fb8a41749587f2f644896a3d
record_format	dspace
spelling	oai:doaj.org-article:43034dd2fb8a41749587f2f644896a3d2021-12-02T11:52:23ZQuantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy10.1038/s41598-017-00759-82045-2322https://doaj.org/article/43034dd2fb8a41749587f2f644896a3d2017-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00759-8https://doaj.org/toc/2045-2322Abstract A major challenge in evaluating the success of HIV eradication approaches is the need for accurate measurement of persistent HIV during effective antiretroviral therapy (ART). Previous studies have reported that the anti-HIV antibody assay “luciferase immuno-precipitation systems (LIPS)” can distinguish HIV-infected individuals harboring different sizes of the viral reservoirs. We performed antibody profiling of HIV-1 proteomes using LIPS in viremic progressors (n = 38), elite controllers (ECs; n = 19) and patients with fully suppressive long-term antiretroviral therapy (ART) (n = 19) (mean 17 years). IgG was quantified against six HIV-1 fusion proteins: p24, gp41, RT, Tat, integrase and protease. Lower antibody levels to all six-fusion proteins were observed in long-term ART patients compared to viremics (p < 0.05). In contrast ECs had lower antibody levels only against Tat and Integrase (p < 0.05). Principal component analysis and cluster-network analysis identified that 68% (13/19) of the long-term ART patients clustered together with 26% (5/19) ECs. The remaining ECs clustered together with the viremics indicating non-homogeneity among the ECs. The low anti-HIV levels in the long-term treated patients may indicate a restricted remaining viral replication. In contrast, the higher levels in ECs suggest a continuous viral expression with a limited concomitant release of extracellular virus.Wang ZhangMohammed M. MorshedKajsa NoyanAman RussomAnders SönnerborgUjjwal NeogiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Wang Zhang Mohammed M. Morshed Kajsa Noyan Aman Russom Anders Sönnerborg Ujjwal Neogi Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
description	Abstract A major challenge in evaluating the success of HIV eradication approaches is the need for accurate measurement of persistent HIV during effective antiretroviral therapy (ART). Previous studies have reported that the anti-HIV antibody assay “luciferase immuno-precipitation systems (LIPS)” can distinguish HIV-infected individuals harboring different sizes of the viral reservoirs. We performed antibody profiling of HIV-1 proteomes using LIPS in viremic progressors (n = 38), elite controllers (ECs; n = 19) and patients with fully suppressive long-term antiretroviral therapy (ART) (n = 19) (mean 17 years). IgG was quantified against six HIV-1 fusion proteins: p24, gp41, RT, Tat, integrase and protease. Lower antibody levels to all six-fusion proteins were observed in long-term ART patients compared to viremics (p < 0.05). In contrast ECs had lower antibody levels only against Tat and Integrase (p < 0.05). Principal component analysis and cluster-network analysis identified that 68% (13/19) of the long-term ART patients clustered together with 26% (5/19) ECs. The remaining ECs clustered together with the viremics indicating non-homogeneity among the ECs. The low anti-HIV levels in the long-term treated patients may indicate a restricted remaining viral replication. In contrast, the higher levels in ECs suggest a continuous viral expression with a limited concomitant release of extracellular virus.
format	article
author	Wang Zhang Mohammed M. Morshed Kajsa Noyan Aman Russom Anders Sönnerborg Ujjwal Neogi
author_facet	Wang Zhang Mohammed M. Morshed Kajsa Noyan Aman Russom Anders Sönnerborg Ujjwal Neogi
author_sort	Wang Zhang
title	Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
title_short	Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
title_full	Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
title_fullStr	Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
title_full_unstemmed	Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
title_sort	quantitative humoral profiling of the hiv-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/43034dd2fb8a41749587f2f644896a3d
work_keys_str_mv	AT wangzhang quantitativehumoralprofilingofthehiv1proteomeinelitecontrollersandpatientswithverylongtermefficientantiretroviraltherapy AT mohammedmmorshed quantitativehumoralprofilingofthehiv1proteomeinelitecontrollersandpatientswithverylongtermefficientantiretroviraltherapy AT kajsanoyan quantitativehumoralprofilingofthehiv1proteomeinelitecontrollersandpatientswithverylongtermefficientantiretroviraltherapy AT amanrussom quantitativehumoralprofilingofthehiv1proteomeinelitecontrollersandpatientswithverylongtermefficientantiretroviraltherapy AT anderssonnerborg quantitativehumoralprofilingofthehiv1proteomeinelitecontrollersandpatientswithverylongtermefficientantiretroviraltherapy AT ujjwalneogi quantitativehumoralprofilingofthehiv1proteomeinelitecontrollersandpatientswithverylongtermefficientantiretroviraltherapy
_version_	1718395043085025280

Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy

Ejemplares similares